(NYSE: BDX) Becton Dickinson & Co's forecast annual revenue growth rate of -2.02% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 10.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Becton Dickinson & Co's revenue in 2026 is $21,924,000,000.On average, 18 Wall Street analysts forecast BDX's revenue for 2026 to be $5,548,478,890,174, with the lowest BDX revenue forecast at $5,328,658,213,626, and the highest BDX revenue forecast at $5,975,591,603,674. On average, 18 Wall Street analysts forecast BDX's revenue for 2027 to be $5,671,772,093,471, with the lowest BDX revenue forecast at $5,448,534,515,215, and the highest BDX revenue forecast at $6,044,783,863,261.
In 2028, BDX is forecast to generate $5,892,446,995,446 in revenue, with the lowest revenue forecast at $5,557,021,144,444 and the highest revenue forecast at $6,352,020,275,172.